{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-006880","form_type":"8-K","ticker":"ATAI","cik":"0002081043","company_name":"AtaiBeckley Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.203785+00:00","generated_at":"2026-05-15T23:53:04.152222+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AtaiBeckley reports positive Phase 2a results for EMP-01 in Social Anxiety Disorder; LSAS -11.85 vs placebo","bullets":["EMP-01 met primary safety objective; no serious AEs, no suicidal behavior.","LSAS placebo-adjusted reduction of 11.85 points at Day 43 (Hedges' g=0.45, p=0.036 one-tailed).","CGI-I responders: 49% EMP-01 vs 15% placebo; NNT 2.95.","Improvements in both Fear (-13.7) and Avoidance (-15.1) subscales after two doses without psychotherapy.","71 patients enrolled, 69 completed Day 43 with high retention."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-006880","json":"https://secwatch.observer/filing/0001140361-26-006880.json","markdown":"https://secwatch.observer/filing/0001140361-26-006880.md","text":"https://secwatch.observer/filing/0001140361-26-006880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126006880/0001140361-26-006880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126006880/ef20066456_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:53:04.152222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}